Meredith M. Regan, ScD
Office phone: 617-632-2471
Preferred contact method: email
Area of Research
Statistical Methods in Cancer Research
Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215
Dr. Regan is Associate Professor of Medicine, Harvard Medical School. She earned her doctorate in Biostatistics from Harvard School of Public Health. After completing a fellowship at the Biometrics Center at Beth Israel Deaconess Medical Center, she joined the faculty at BIDMC, and in 2003 joined the Dana-Farber Cancer Institute Department of Biostatistics and Computational Biology. Dr. Regan was appointed Group Statistician for the International Breast Cancer Study Group (IBCSG) in 2009 and is a member of the IBCSG Scientific Executive Committee.
ResearchStatistical Methods in Cancer Research
Dr. Regan’s research focuses on clinical and translational research in breast and genitourinary cancers. She is Director of the Biostatistics and Computational Biology Core of the DF/HCC Prostate Cancer SPORE, past Core Director of the DF/HCC Kidney Cancer SPORE, and Core Co-Director of the DF/HCC Breast Cancer SPORE. In a new initiative led by Dr. Christopher Sweeney, the Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP) Working Group is conducting an individual patient data meta-analysis to evaluate surrogate endpoints for overall survival in randomized clinical trials for localized prostate cancer treatment.
Dr. Regan is Group Statistician for the International Breast Cancer Study Group (IBCSG). She is the lead statistician for the international randomized clinical trials SOFT and TEXT evaluating the adjuvant endocrine therapy in premenopausal women with early-stage breast cancer. With IBCSG colleagues, her translational research focuses on features of the disease or patient that inform selection of endocrine therapy for individual patients.
Dr. Regan’s statistical research focuses on long-term analysis of randomized clinical trials with selective crossover, in which patients on the control arm are provided the opportunity to take the experimental treatment after first dissemination of the trial’s results; the work is motivated by the international BIG 1-98 and HERA trials adjuvant early breast cancer trials.
- Colleoni M, Giobbie-Hurder A, Regan MM, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Lang I, Smith I, Chirgwin J, Pienkowski T, Wardley A, Price KN, Gelber RD, Coates AS, Goldhirsch A. Analyses adjusting for selective crossover show improved overall survival with adjuvant letrozole compared with tamoxifen in the BIG 1-98 study. J Clin Oncol 2011;29:1117-24.
- Alemozaffar* M, Regan* MM, Cooperberg MR, Wei JT, Michalski JM, Sandler HM, Hembroff L, Sadetsky N, Saigal CS, Litwin MS, Klein E, Kibel AS, Hamstra DA, Pisters LL, Kuban DA, Kaplan ID, Wood DP, Ciezki J, Dunn RL, Carroll PR**, Sanda MG**. Prediction of erectile function following treatment for prostate cancer. JAMA 2011;306:1205-14.
- Dowsett M, Nielsen TO, A’Hern R, Bartlett J, Coombes RC. Cuzick J, Ellis M, Henry NL, Hugh JC, Lively T, McShane L, Paik S, Prudkin L, Regan M, Salter J, Sotririou C, Smith IE, Viale G, Zujewski JA, Hayes DF. Assessment of Ki67 in breast cancer: Recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst 2011;103:1656-64.
- Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L, Forbes JF, Smith I, Lang I, Wardley A, Rabaglio M, Price KN, Gelber RD, Coates AS, Thurlimann B, for the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group (IBCSG). Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up. Lancet Oncol 2011;12:1101-8.
- Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Láng I, Gomez HL, Tondini C, Burstein HJ, Perez EA, Ciruelos E, Stearns V, Bonnefoi HR, Martino S, Geyer CE Jr, Pinotti G, Puglisi F, Crivellari D, Ruhstaller T, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Bernhard J, Luo W, Ribi K, Viale G, Coates AS, Gelber RD, Goldhirsch A, Francis PA; TEXT and SOFT Investigators and the International Breast Cancer Study Group. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 2014 Jul 10;371(2):107-18.
- Francis* PA, Regan* MM, Fleming GF, Láng I, Ciruelos E, Bellet M, Bonnefoi HR, Climent MA, Da Prada GA, Burstein HJ, Martino S, Davidson NE, Geyer, Jr. CE, Walley BA, Coleman R, Kerbrat P, Buchholz S, Ingle JN, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Colleoni M, Viale G, Coates AS, Goldhirsch A, Gelber RD; SOFT Investigators and the International Breast Cancer Study Group. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 2015 Jan 29;372(5):436-46. Epub 2014 Dec 11.
- McDermott DF, Cheng SC, Signoretti S, Margolin KA, Clark JI, Sosman JA, Dutcher JP, Logan TF, Curti BD, Ernstoff MS, Appleman L, Wong MK, Khushalani NI, Oleksowicz L, Vaishampayan UN, Mier JW, Panka DJ, Bhatt RS, Bailey AS, Leibovich BC, Kwon ED, Kabbinavar FF, Belldegrun AS, Figlin RA, Pantuck AJ, Regan MM, Atkins MB. The high-dose aldesleukin "Select" trial: A trial to prospectively validate predictive models of response treatment in patients with metastatic renal cell carcinoma. Clin Cancer Res 2015 Feb 1;21:561-8. Epub 2014 Nov 25.
- Regan MM, Francis PA, Pagani O, Fleming GF, Walley BA, Viale G, Colleoni M, Láng I, Gómez HL, Tondini C, Pinotti G, Price KN, Coates AS, Goldhirsch A, Gelber RD for the SOFT and TEXT Investigators and International Breast Cancer Study Group. Absolute benefits of adjuvant endocrine therapies for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials. J Clin Oncol 2016 Jul 1;34(19);2221-31. Epub 2016 Apr 4.